匹多莫德降低肺癌化疗患者肺内感染的临床研究  

Clinical study of pidotimod in reducing pulmonary infection in patients with lung cancer undergoing chemotherapy

作　　者：孙国瑞 徐姝丽 姚洪莹 刘涛 程谟朝 刘静 王琦超 唐淑红 Sun Guorui;Xu Shuli;Yao Hongying;Liu Tao;Cheng Mozhao;Liu Jing;Wang Qichao;Tang Shuhong(Second Department of Pneumology,the Fifth People′s Hospital of Dalian City,Dalian 116021,China)

机构地区：[1]大连市第五人民医院胸内二科,116021

出　　处：《中国医师进修杂志》2021年第5期430-433,共4页Chinese Journal of Postgraduates of Medicine

基　　金：大连市医学科学研究计划(1711051)。

摘　　要：目的探讨匹多莫德降低肺癌化疗患者肺内感染的效果。方法选取大连市第五人民医院2017年7月至2018年7月肺癌患者120例,将患者按随机数字表法分为对照组和匹多莫德组,每组60例。两组患者根据病理类型分别选取相应标准含铂两药方案化疗,匹多莫德组患者口服匹多莫德。观察两组患者化疗过程中发生肺内感染的次数、按期完成化疗例数及不良反应等。应用多因素有序Logistic回归分析肺内感染与应用匹多莫德的相关性。结果匹多莫德组肺内感染发生率明显低于对照组[18.33%(11/60)比40.00%(24/60)],差异有统计学意义(χ^(2) = 6.845,P<0.01)。匹多莫德组按期完成化疗率明显高于对照组[55.00%(33/60)比36.67%(22/60)],差异有统计学意义(χ^(2) = 4.062,P<0.05)。多因素有序Logistic回归分析结果显示,应用匹多莫德可降低肺内感染风险(OR = 0.210,95%CI 0.072~0.606,P = 0.004),并有助于化疗周期完成(OR = 2.323,95%CI 1.080~5.003,P = 0.031)。匹多莫德组未监测到与应用匹多莫德有关的明显不良反应,未影响患者化疗。结论应用匹多莫德可降低肺癌化疗患者肺内感染率,有助于患者按计划完成化疗。Objective To investigate the effect of pidotimod in reducing pulmonary infection in patients with lung cancer undergoing chemotherapy.Methods One hundred and twenty patients with lung cancer in the Fifth People′s Hospital of Dalian City from July 2017 to July 2018 were selected.The patients were divided into control group and pidotimod group by random digits table method with 60 cases each.The patients were treated with standard two drugs chemotherapy containing platinum drug according to the pathological type,and the patients in pidotimod group were combined with pidotimod.The number of pulmonary infections during chemotherapy,number of completed scheduled chemotherapy and adverse reaction were observed.The correlation between pulmonary infection and pidotimod was analyzed by multivariate orderly Logistic regression.Results The incidence of pulmonary infection in pidotimod group was significantly lower than that in control group:18.33%(11/60)vs.40.00%(24/60),and there was statistical difference(χ^(2)=6.845,P<0.01).The rate of completed scheduled chemotherapy in pidotimod group was significantly higher than that in control group:55.00%(33/60)vs.36.67%(22/60),and there was statistical difference(χ^(2)=4.062,P<0.05).Multivariate orderly Logistic regression analysis result showed that pidotimod could reduce the risk of pulmonary infection(OR=0.210,95%CI 0.072 to 0.606,P=0.004),and help to complete the scheduled chemotherapy(OR=2.323,95%CI 1.080 to 5.003,P=0.031).In pidotimod group,no obvious adverse reaction related to pidotimod application was detected,and chemotherapy was not affected.Conclusions Application of pidotimod can reduce the chance of pulmonary infection in patients with lung cancer undergoing chemotherapy and help patients complete scheduled chemotherapy.

关 键 词：肺肿瘤 药物疗法 感染 匹多莫德 

分 类 号：R734.2[医药卫生—肿瘤]